• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
AOF
Click for more information
2.68% 11.5¢

AoFrio Limited Ordinary Shares

watchlist Created with Sketch. Add to my watchlist
Industrials

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
AOF
Ann: Disclosure of director's relevant interest 		10/09/24 0 59
10/09/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  59 
AOF
Ann: Solution to reduce energy use and carbon emissions 		29/08/24 2 619
29/08/24 Last post  hatmopit Comments Created with Sketch.  2  Views Created with Sketch.  619 
AOF
Ann: H1 FY24 Results and Guidance Update 		29/08/24 1 259
29/08/24 Last post  Christian Dyor Comments Created with Sketch.  1  Views Created with Sketch.  259 
AOF
Ann: AoFrio H1 2024 Investor Presentation 		02/08/24 0 172
02/08/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  172 
AOF
Ann: H1 2024 Results Announcement and Interim Report release 		31/07/24 0 55
31/07/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  55 
AOF
Ann: AoFrio has another strong quarter, Q2 revenue growth of 41% 		22/07/24 0 86
22/07/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  86 
AOF
Ann: Results of 2024 ASM 		29/05/24 0 105
29/05/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  105 
AOF
Ann: 2024 ASM Meeting Address 		29/05/24 0 119
29/05/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  119 

See All Discussions arrow Created with Sketch.

Featured News

NEWS Significant increase in revenue from faster NDIS approvals and launch of new leasing programs
right-arrow Created with Sketch.
NEWS Significant shallow gold intersections at Tambourah King reveal potential extensions to the lode gold system, with promising RC drill results and more assays pending
right-arrow Created with Sketch.
NEWS Gold mineralisation discovered along major shear zone at Challa Gold Project, confirming two new intersections in latest aircore drilling
right-arrow Created with Sketch.
NEWS High-grade gold discovery at Didievi Project: First drill results reveal impressive 33m intercept at 2.4g/t
right-arrow Created with Sketch.
LU7 Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
right-arrow Created with Sketch.
NEWS Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03
right-arrow Created with Sketch.
(20min delay)
Last
11.5¢ 		Change
0.003(2.68%) 		Mkt cap ! n/a
Open High Low Value Volume
11.3¢ 11.5¢ 11.3¢ $12.66K 111.5K

Buyers (Bids)

No. Vol. Price($)
0 21734 11.3¢
 

Sellers (Offers)

Price($) Vol. No.
11.5¢ 21267 0
Last trade - 12.23pm 07/10/2024 (20 minute delay) ?
AOF (NZSX) Chart

Top Stories

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial.
Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome Neuren has confirmed it's received "positive" FDA responses for its Phase III trial to treat children with Phelan-McDermid syndrome.
Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program Arika Resources Ltd has received commitments from investors in support of a Placement worth $3.2 million to support gold exploration in WA
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03 Nyrada Inc has completed an in-vivo micronucleus on the effects of its NYR-BI03 drug on rats, suggesting it causes no genetic damage

Featured News

NEWS Second consecutive quarter of record revenue driven by strong sales growth in market-leading medical products!
right-arrow Created with Sketch.
NEWS Step out drilling confirms high-grade cobalt & associated copper at Bald Hill
right-arrow Created with Sketch.
NEWS Exciting new copper-gold discoveries at Tarraji-Yampi: Dive into the strong drilling results now
right-arrow Created with Sketch.
NEWS Significant shallow gold intersections at Tambourah King reveal potential extensions to the lode gold system, with promising RC drill results and more assays pending
right-arrow Created with Sketch.
NEWS Positive diamond results allow for scoping study update
right-arrow Created with Sketch.
NEWS Antler Copper Project hits major permitting milestone – air quality permit advances to final review
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.